医疗反应不佳,许多高频疾病的药物治疗失败,比如癌症和病毒感染,已被广泛记录。在这种情况下,许多金属基物质,包括顺铂,auranofin,各种金金属药物,和钌络合物,正在研究可能的抗癌和抗病毒药物。两种Ru(III)和Ru(II)配合物,即,BOLD-100和RAPTA-C,目前正在临床试验和临床前研究评估中进行研究,分别,作为抗癌剂。有趣的是,BOLD-100最近还证明了对SARS-CoV-2的抗病毒活性,SARS-CoV-2是导致COVID-19大流行的病毒。在过去的几年里,许多努力已经致力于发现新的双重抗癌抗病毒药物。Ru基络合物在这方面可能是非常适合的。因此,这篇综述的重点是关于新合成的Ru(II)配合物用作抗癌和/或抗病毒药物的最新研究。
Poor responses to medical care and the failure of pharmacological treatment for many high-frequency diseases, such as cancer and viral infections, have been widely documented. In this context, numerous metal-based substances, including cisplatin, auranofin, various gold metallodrugs, and ruthenium complexes, are under study as possible anticancer and antiviral agents. The two Ru(III) and Ru(II) complexes, namely, BOLD-100 and RAPTA-C, are presently being studied in a clinical trial and preclinical studies evaluation, respectively, as anticancer agents. Interestingly, BOLD-100 has also recently demonstrated antiviral activity against SARS-CoV-2, which is the virus responsible for the COVID-19 pandemic. Over the last years, much effort has been dedicated to discovering new dual anticancer-antiviral agents. Ru-based complexes could be very suitable in this respect. Thus, this review focuses on the most recent studies regarding newly synthesized Ru(II) complexes for use as anticancer and/or antiviral agents.